GW Pharmaceuticals gets FDA Approval for Cannabinoid Prescription Medicine

GW Pharmaceuticals plc GWPH , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced on June 25th, that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.

“Today’s approval of EPIDIOLEX is a historic milestone, offering patients and their families the first and only FDA-approved CBD medicine to treat two severe, childhood-onset epilepsies,” said Justin Gover, GW’s

...read more at http://chasingmarkets.com/news/15b3a7092680e7/GW_Pharmaceuticals_gets_FDA_Approval_for_Cannabinoid_Prescription_Medicine